Non-Accredited Education
Understanding Collagen Dressings and their Benefit in Wound Care Complimentary Archived Webcast
Non-Accredited
Issue
- Issue:10
Disclosure: Dr. Fife is Chief Medical Officer for Intellicure Inc. David Walker is President and CEO of Intellicure Inc.
- Issue:10
Wound healing occurs in 3 overlapping phases: the inflammatory phase (“lag phase”), the proliferative phase (tissue formation), and the remodeling phase. In the proliferative phase, aside from angiogenesis, granulation tissue is formed and the wound is re-epithelialized.1 In the authors’ wound clinic, re-epithelialization after successful debridement and granulation is sometimes the most difficult part of the wound closureprocess. Sometimes the wounds are very large and are preferably closed by split-thickness skin grafting.
- Issue:10
Thoracic empyema (TE) remains a surgical challenge and is associated with substantial morbidity and mortality.
- Issue:10
More than 1000 different occlusive dressings are commercially available.1 Occlusion may enhance wound healing primarily through the prevention of wound desiccation.As a result, epidermal necrosis and eschar formation do not occur, and wounds reepithelialize more rapidly.2–7 However, the benefits of occlusive wound dressings remain sub judice for some.8–15 Some animal studies indicate that fully occlusive dressings may suppress barrier recovery and reduce the epidermal proliferative response to an abnormal stratum corneum barrier.8–11
- Issue:10
The term tissue engineering was introduced in 1987 during a meeting of the National Science Foundation. It is the application of principles and methods of engineering and life sciences toward the fundamental understanding of structure-function relationships in normal and pathological mammalian tissue, and the development of biological substitutes to restore, maintain, or improve tissue function.1 Tissue engineering can be considered a multidisciplinary technology used to reach a universal goal—to grow and expand tissues in vitro from donor cells (grow-your-own).
- Issue:10
AutoloGel™ Platelet Rich Plasma Receives Marketing Clearance
Press Release
ConvaTec and Boehringer Technologies Announce License Agreement
ConvaTec Acquires Exclusive Worldwide Rights for a Negative Pressure Wound Therapy System
SKILLMAN, NJ (December 18, 2008) — ConvaTec, a world-leading developer and marketer of innovative medical technologies for community and hospital care, announced today it has signed a long-term global exclusive license agreement with Boehringer Technologies to market and distribute Boehringer’s Engenex® Negative Pressure Wound Therapy (NPWT) System incorporating Bio-Dome™ Interface Technology.
WOUNDS News Wire
- Friday, December 5, 2008 - 15:08
- Wednesday, October 22, 2008 - 15:28
- Wednesday, October 22, 2008 - 15:25
CME Showcase
"Diabetic Peripheral Neuropathy"
Upcoming Accredited Webcast Release Date: December 22, 2008 Expiration Date: December 22, 2009 This activity is supported by an educational grant from PamLabs. To register for this Webcast, visit www.naccme.com/program/n-558/ |
"Current Concepts In Healing Chronic Diabetic Foot Ulcerations"
Upcoming Live Accredited Webcast with Q&A Noon to 1 p.m. EDT January 20, 2009 Rebroadcasts 7:30-8:30 p.m. EDT 3-4 p.m. EDT This activity is supported by an educational grant from Advanced Biohealing. To register for this Webcast, visit www.naccme.com/program/n-550/ |
| MRSA And Diabetic Foot Wounds: Where Do We Go From Here? Accredited Webcast Archive Version available now. This activity is supported by an educational grant from Pfizer. This activity is sponsored by the North American Center For Continuing Medical Education (NACCME). |
|
PERIPHERAL ARTERIAL DISEASE (PAD) AND CRITICAL LIMB ISCHEMIA (CLI): Managing Vascular and Wound Healing Challenges with Current and Emerging Technologies Maintenance Debridement: A New Look at Science and Art Accredited Webcast with Q&A: November 17, 2008 at 3:00pm EST This activity is supported by an educational grant from HealthPoint Ltd. |








